Acumed | OsteoMed is pleased to announce the opening of our new logistics center in Madrid, Spain, that will enhance our customer experience in the European Union (EU) by reducing delivery times, mitigating supply chain risks, and accelerating growth.
The Acumed Fibula Nail 2 System is designed to provide an alternate treatment to bone plating by offering a less invasive intramedullary approach to fractures of the fibula.
The Acumed | OsteoMed PFX Choice™ program is designed to help customers choose the right combination of products, customer service, payment, and billing options to meet their unique needs.
Acumed | OsteoMed is proud to be Certified™ by Great Place to Work®. This prestigious award is based entirely on what current employees say about their experience working at Acumed | OsteoMed. This year, 80% of employees said it’s a great place to work – 21 points higher than the average US company.
The combined Acumed | OsteoMed organization will be structured into Business Units whose leaders will be responsible for global sales, marketing, and research and development.
Acumed’s ASCent is a customizable program designed to provide Ambulatory Surgery Centers (ASCs) with numerous options to meet in situ challenges for optimal patient outcomes.
Colson Medical, LLC is pleased to announce the merger of two Colson Medical companies, Acumed and OsteoMed. Operations will be integrated gradually over the coming year while maintaining both global brands.
In partnership with Professor Mohit Bhandari, MD, of McMaster University, Acumed has committed to providing high-quality data that assists the health care community in creating care pathways to treat upper and lower extremity injuries.
Acumed is excited to welcome Acute Innovations, a manufacturer of innovative solutions for challenging traumatic chest wall injuries, to join us in developing industry-first products and sharing our commitment to Education, Evidence, Innovation, and Quality. The Acute product portfolio specifically offers surgeons solutions to address rib fractures associated with traumatic injury, as well as technologies for chest wall reconstruction.
Acumed LLC today announced that it has entered into an agreement with Vivorte Inc. to be the exclusive distributor of the Louisville-based company’s orthobiologics portfolio. Under the terms of the agreement, Acumed will employ its sales, marketing, and medical education expertise to distribute Vivorte’s calcium phosphate-based bone allograft (Trabexus) and calcium phosphate-based biocement (Fortera). Vivorte will continue to utilize its product development and manufacturing capabilities to support the distribution.
